Aquatic Capital Management LLC Buys Shares of 303,448 Novo Nordisk A/S $NVO

Key Points

• Aquatic Capital Management established a new position of 303,448 Novo Nordisk shares in Q3, valued at about $16.84 million.
• Novo Nordisk beat quarterly estimates with $1.01 EPS on $12.43 billion revenue and declared a dividend of $1.2751 per share (record Mar 30, paid Apr 8).
• Regulatory and legal headwinds — including an FDA warning over unreported semaglutide adverse events and a related investor investigation — have pressured the stock, and analysts on balance rate NVO as a "Hold" (average price target $49.93).

Aquatic Capital Management LLC purchased a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 303,448 shares of the company's stock, valued at approximately $16,838,000.

A number of other institutional investors have also added to or reduced their stakes in NVO. Arrow Capital Pty Ltd bought a new stake in shares of Novo Nordisk A/S during the third quarter valued at about $3,884,000. Warther Private Wealth LLC increased its holdings in Novo Nordisk A/S by 2.6% during the 3rd quarter. Warther Private Wealth LLC now owns 407,995 shares of the company's stock worth $22,640,000 after acquiring an additional 10,263 shares during the period. Lazard Asset Management LLC lifted its stake in Novo Nordisk A/S by 12.4% in the 3rd quarter. Lazard Asset Management LLC now owns 1,421,526 shares of the company's stock worth $78,880,000 after purchasing an additional 157,344 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at $1,904,000. Finally, Logan Capital Management Inc. increased its holdings in shares of Novo Nordisk A/S by 86.8% in the third quarter. Logan Capital Management Inc. now owns 20,071 shares of the company's stock worth $1,114,000 after purchasing an additional 9,324 shares during the period. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Down 0.1%

Shares of NYSE NVO opened at $37.99 on Friday. The stock has a market capitalization of $169.61 billion, a P/E ratio of 10.95 and a beta of 0.73. Novo Nordisk A/S has a one year low of $35.85 and a one year high of $82.57. The firm's 50 day simple moving average is $50.14 and its two-hundred day simple moving average is $51.77. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. As a group, analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be paid a dividend of $1.2751 per share. This represents a dividend yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S's dividend payout ratio (DPR) is 52.74%.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo’s deal with telehealth/retail player Hims & Hers could broaden channels for GLP‑1 distribution and shift competitive dynamics in the obesity market; Hims shares have surged on the tie-up. Hims shares set for best week on record after new Novo Nordisk deal
• Positive Sentiment: Novo’s partnership with the WHO Foundation to support cardio‑renal‑metabolic programs expands its public‑health footprint and may support long‑term access and reputation in emerging markets. Novo Nordisk WHO Partnership Links Global Health Push With Valuation Story
• Neutral Sentiment: Zacks moved NVO from “strong sell” to “hold,” which slightly reduces near‑term sell‑side pressure but is not a bullish upgrade. Zacks.com
• Neutral Sentiment: Broader health‑care weakness today (NYSE Health Care Index decline) is adding to headline pressure across large pharma names, including NVO. Sector Update: Health Care Stocks Retreat Late Afternoon
• Negative Sentiment: The FDA issued a warning to Novo Nordisk about unreported semaglutide adverse events — the clearest near‑term catalyst for the share decline as it raises risks of inspections, disclosures, labeling changes, prescribing impacts and regulatory enforcement. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: An investor class‑action/investigation notice (Pomerantz) has been announced, increasing legal risk and potential future claims tied to the disclosure of safety events. Pomerantz investor alert
• Negative Sentiment: Analyst downgrades and negative press—plus reporting that Novo Holdings’ assets shrank after the stock slump—are reinforcing selling momentum and investor concern about valuation and control‑group exposure. Novo Nordisk stock slump hits value of controlling shareholder

Wall Street Analyst Weigh In

Several equities analysts recently commented on NVO shares. JPMorgan Chase & Co. restated a "neutral" rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. HSBC restated a "hold" rating and issued a $54.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Zacks Research raised shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 10th. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "hold" rating in a research report on Thursday, February 12th. Finally, Nordea Equity Research lowered shares of Novo Nordisk A/S to a "hold" rating in a research report on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating and nineteen have given a Hold rating to the stock. According to data from MarketBeat, Novo Nordisk A/S has an average rating of "Hold" and an average price target of $49.93.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.